Day: March 7, 2022

Graphex Group Files Registration Statement for Proposed Listing on NYSE American

Written by Customer Service on March 7, 2022. Posted in Public Companies.

HONG KONG, March 07, 2022 (GLOBE NEWSWIRE) — Graphex Group Limited (“Graphex”) (OTCQX: GRFXY | HKSE: 6128), has publicly filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to its proposed public offering (“Offering”) of American Depositary Shares (“ADS”). The Offering will raise additional capital to Graphex which will be used, primarily, to expand its graphene business to support global demand. The number of ADS to be offered and the price range for the proposed offering have not yet been determined. Graphex will apply to list the receipts representing the ADS on the NYSE American stock exchange market under the symbol “GRFX” and expects to have the listing complete concurrent with the closing...

Kraig Biocraft Laboratories Collaboration Between US and Vietnam Teams Completes First 100% Genetic Screening for In-Process Spider Silk Production

Written by Customer Service on March 7, 2022. Posted in Public Companies.

ANN ARBOR, Mich., March 07, 2022 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announced significant advancements in its Vietnam based production facility, Prodigy Textiles. The collaboration between the Company’s US and Vietnam lab teams has resulted in their first complete genetic screening of in-process production silkworms. This fifth generation of silkworms, now being reared in Vietnam, is the first production cycle of silkworms at the factory to receive 100% genetic screening. This level of testing, for Kraig Labs, was previously only available at the Company’s R&D headquarters is now being fully transferred to the Vietnamese lab team. Earlier...

Verizon announces an increase to the waterfall cap and early participation results for tender offers for 30 series of debt securities of Verizon and certain of its subsidiaries

Written by Customer Service on March 7, 2022. Posted in Public Companies.

NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) — Verizon Communications Inc. (“Verizon”) (NYSE, NASDAQ: VZ) today announced that, in connection with the Offers (as defined below), all Notes (as defined below) validly tendered and not validly withdrawn at or prior to the Early Participation Date (as defined below) will be accepted for purchase, in accordance with the terms of the Offer to Purchase (as defined below). As a result, the Waterfall Cap (as defined below) will be increased from a total cash amount of up to $4.0 billion to a total cash amount sufficient to accept for purchase all notes tendered prior to the Early Participation Date (approximately $5.6 billion). Verizon also announced the early participation results, as of 5:00 p.m. (Eastern time) on March 4, 2022 (the “Early Participation Date”), of its previously announced...

Aravive to Participate In-Person at 34th Annual ROTH Conference

Written by Customer Service on March 7, 2022. Posted in Public Companies.

HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, will participate in an in-person fireside chat at the 34th Annual ROTH Conference on Monday, March 14, 2022, at 8:30 am PT in HEALTHCARE VFC – Suite 2022 at The Ritz Carlton, Dana Point, California. Dr. McIntyre and Vinay Shah, Chief Financial Officer of Aravive, will be available for one-on-one meetings on Monday, March 14th. A live webcast and a replay of the presentation will be available on Events & Presentations page of www.aravive.com. About AraviveAravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease. Our...

Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULON™

Written by Customer Service on March 7, 2022. Posted in Public Companies.

The parties have entered into a collaboration agreement to develop Targovax´s TG mutant KRAS cancer vaccines in combination with Agenus´s QS-21 STIMULON adjuvant technology The agreement may be extended into an exclusive commercial partnership for KRAS vaccination if the combination proves effective in exploratory clinical studiesLEXINGTON, Mass., March 07, 2022 (GLOBE NEWSWIRE) — Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, and Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announce that they have entered into a clinical collaboration and supply agreement to combine Targovax’s TG mutant KRAS...

EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory Officer

Written by Customer Service on March 7, 2022. Posted in Public Companies.

WATERTOWN, Mass., March 07, 2022 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the appointment of Isabelle Lefebvre as Chief Regulatory Officer. Ms. Lefebvre brings over 30 years of global regulatory affairs experience across all phases of drug development including ophthalmic and ocular conditions. Ms. Lefebvre is succeeding John Weet, Ph.D., who be leaving his role as Senior Vice President, Regulatory, following a transition period. “Isabelle brings a wealth of regulatory strategy experience from large and midsize global pharmaceutical companies along with a strong track record of leading successful drug approvals in the ocular space, and we are...

Builders FirstSource Hires Amy Bass Messersmith as Chief People Officer

Written by Customer Service on March 7, 2022. Posted in Public Companies.

Builders FirstSource Hires Amy Bass Messersmith as Chief People Officer Amy Bass Messersmith, Chief People Officer, Builders FirstSourceDALLAS, March 07, 2022 (GLOBE NEWSWIRE) — Builders FirstSource, Inc. (NYSE: BLDR) (“Builders FirstSource”), today announced that Amy Bass Messersmith will be joining Builders FirstSource as its Chief People Officer, effective March 14, 2022. In this role, Ms. Messersmith will be a member of the Builders FirstSource executive leadership team, overseeing all aspects of human resources, including the implementation of strategies to develop and promote best practices in organizational and leadership development, diversity and inclusion, and talent acquisition, development, and management. “We are excited to bring Ms. Messersmith on as Chief People Officer, and I am confident that her strong and...

Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results

Written by Customer Service on March 7, 2022. Posted in Earnings Releases And Operating Results.

Q4 2021 net loss was $(0.48) per basic and diluted share and adjusted non-GAAP net income* was $0.87 per basic and $0.85 per diluted share FY 2021 net loss was $(0.66) per basic and diluted share and adjusted non-GAAP net income* was $2.64 per basic and $2.59 per diluted share Early trends1 indicate that Q1 2022 revenue is expected to be in the range of $120 million – $130 million and adjusted non-GAAP earnings per share* in the range of $3.80 – $4.10 Commenced shipment of vasopressin, a generic alternative to Vasostrict®, with 180 days of marketing exclusivity Announced commercial availability of novel product, PEMFEXY™ (pemetrexed for injection), a branded alternative to ALIMTA® On track to support submission of new drug application in second quarter of 2022 for Landiolol, a beta-1 adrenergic blockerExpects to start clinical...

Triterras Reports Fiscal Year-End February 2021 Results

Written by Customer Service on March 7, 2022. Posted in Earnings Releases And Operating Results.

SINGAPORE, March 07, 2022 (GLOBE NEWSWIRE) — Triterras Inc. (OTC Expert Market: TRIRF) (“Triterras” or the “Company”), a leading fintech company focused on trade and trade finance, today reported its audited financial results for the fiscal year ended February 28, 2021 (fiscal 2021). “We are pleased to report our fiscal 2021 results, which represented a solid year for Triterras, highlighted by revenue growth of 228% and adjusted EBITDA growth of 78% compared to fiscal 2020, as our Kratos™ platform continued to scale and expand its network of traders and lenders,” said Triterras’ Chairman and CEO Srinivas Koneru. “We view fiscal 2021 as a very successful year considering industry headwinds that began to appear towards the end of our fiscal year related to global supply chain constraints and liquidity shortfalls in trade finance.” Mr....

Substation Market to Touch USD 173.64 Billion by 2028; L&T Received Turnkey Construction Contract for 380 kV Substation in Saudi Arabia: Fortune Business Insights™

Written by Customer Service on March 7, 2022. Posted in Mergers And Acquisitions.

Companies Profiled in the Substation Market Report: GE (U.S.), NR Electric Co., Ltd. (China), Siemens (Germany), Hitachi ABB Power Grids (Switzerland), Schneider Electric (France), Eaton (Ireland), Efacec (Portugal), Rockwell Automation (U.S.), Emerson (U.S.), Belden (U.S.), L&T Electrical & Automation (India), Texas Instruments Incorporated (U.S.) Pune, India, March 07, 2022 (GLOBE NEWSWIRE) — The substation market size was valued at USD 124.52 billion in 2020. The market is expected to rise from USD 128.25 billion in 2021 to USD 173.64 billion by 2028 at a 4.4% CAGR during the forecast period 2021-2028. Fortune Business Insights™ has deep-dived into these insights in its latest research report titled, “Substation Market, 2021-2028.” According to the study, substation equipment will be sought across end-use applications,...

Day: March 7, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals